Announced Date: 2024-01-02 (January 2, 2024)<\/p>\n\n\n\n
Asset Name: YL211 (RG6648)<\/p>\n\n\n\n
Licensor: MediLink (MediLink Therapeutics, China) <\/p>\n\n\n\n
Licensee (Buyer): Roche<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Asset Modality: ADC (antibody drug conjugate) <\/p>\n\n\n\n
Asset Target: c-Met (c-Mesenchymal epithelial transition factor)<\/p>\n\n\n\n
Potential Indication: Solid tumors<\/p>\n\n\n\n
Current Stage: IND stage<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Scope of Authority: <\/p>\n\n\n\n
MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of MediLink\u2019s ADC asset, YL211. <\/p>\n\n\n\n
MediLink will work together with Roche\u2019s R&D unit China Innovation Center of Roche (CICoR) to initiate the Phase I clinical trial of YL211 and Roche will then take over the further development and commercialization globally. <\/p>\n\n\n\n
.<\/p>\n\n\n\n
Payment Detail:<\/p>\n\n\n\n
Upfront and near-term milestone payments of $50 million,<\/p>\n\n\n\n
Total payments up to $1 billion.<\/p>\n\n\n\n
Tiered royalties on net sales.<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Link:<\/p>\n\n\n\n
MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation ADC in Oncology<\/p>\n\n\n\n